Use of Factor v Leiden genetic testing in practice and impact on management

Genetics in Medicine

Volumn 11, Issue 10, 2009, Pages 750-756

  Laberge, Anne Marie ^a   Psaty, Bruce M ^a   Hindorff, Lucia A ^b   Burke, Wylie ^a,c  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b Department of Epidemiology

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Clinical practice guidelines; Clinical utility; Factor V Leiden; Genetic test; Patient management

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN;

ADULT; ARTICLE; CLINICAL ASSESSMENT; CLINICAL PRACTICE; CONTROLLED STUDY; GENETIC ANALYSIS; GENETIC RISK; HEALTH CARE SYSTEM; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; OUTCOME ASSESSMENT; PATIENT CARE; PHYSICIAN; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE;

ACTIVATED PROTEIN C RESISTANCE; ATTITUDE OF HEALTH PERSONNEL; FACTOR V; FEMALE; GENETIC TESTING; GUIDELINE ADHERENCE; HUMANS; MALE; MIDDLE AGED; PROFESSIONAL PRACTICE; RATIONALIZATION; RETROSPECTIVE STUDIES;

EID: 70350221025     PISSN: 10983600     EISSN: None     Source Type: Journal    
DOI: 10.1097/GIM.0b013e3181b3a697     Document Type: Article

References (21)

1. Collins FS, McKusick VA. Implications of the Human Genome Project for Medical Science. JAMA 2001;285:540-544.
2. Collins FS, Green ED, Guttmacher AE, Guyer MS. A vision for the future of genomics research. Nature 2003;422:835-847.
3. Emmerich J, Rosendaal FR, Cattaneo M, et al. Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism-pooled analysis of 8 case-control studies including 2310 cases and 3204 controls. Study Group for Pooled-Analysis in Venous Thromboembolism. Thromb Haemost 2001;86:809-816.
4. Langlois NJ, Wells PS. Risk of venous thromboembolism in relatives of symptomatic probands with thrombophilia: a systematic review. Thromb Haemost 2003;90:17-26.
5. Wu O, Robertson L, Twaddle S, et al. Screening for thrombophilia in high-risk situations: systematic review and cost-effectiveness analysis. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) study. Health Technol Assess 2006;10:1-110.
6. Rey E, Kahn SR, David M, Shrier I. Thrombophilic disorders and fetal loss: a meta-analysis. Lancet 2003;361:901-908.
7. Kovalevsky G, Gracia CR, Berlin JA, Sammel MD, Barnhart KT. Evaluation of the association between hereditary thrombophilias and recurrent pregnancy loss: a meta-analysis. Arch Intern Med 2004;64:558-563.
8. Rosendaal FR, Siscovick DS, Schwartz SM, et al. Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women. Blood 1997;89:2817-2821.
9. Grody WW, Griffin JH, Taylor AK, Korf BR, Heit JA. American College of Medical Genetics consensus statement on factor V Leiden mutation testing. Genet Med 2001;3:139-148.
10. Press RD, Bauer KA, Kujovich JL, Heit JA. Clinical utility of factor V Leiden (R506Q) testing for the diagnosis and management of thromboembolic disorders. Arch Pathol Lab Med 2002;126:1304-1318.
11. Spector EB, Grody WW, Matteson CJ, et al. Technical standards and guidelines: venous thromboembolism (factor V Leiden and prothrombin 20210G >A testing): a disease-specific supplement to the standards and guidelines for clinical genetics laboratories. Genet Med 2005;7:444-453
12. Deep Vein Thrombosis Treatment Guideline. DP-1036. Group Health Cooperative, 2002.
13. Deep Vein Thrombosis Treatment Guideline. DP-1036. Group Health Cooperative, 2003. Gene Tests website. Available at http://www.genetests.org/.
14. Rodger MA, Carrier M, Keely E, et al. The management of thrombophilia during pregnancy: a Canadian survey. J Obstet Gynaecol Can 2002;24:946-952.
15. Grimshaw JM, Thomas RE, MacLennan G, et al. Effectiveness and efficiency of guideline dissemination and implementation strategies. Health Technol Assess 2004;8:iii-iv, 1-72.
16. John BJ, Irukulla S, Mendall MA, Abulafi AM. Do guidelines improve clinical practice?-A National Survey on Surveillance Colonoscopies. [published online ahead of print April 10, 2009.] Colorectal Dis. doi://10.111/ j.1463-1318.2009.01869.x.
17. Riegert-Johnson DL, Macaya D, Hefferon TW, Boardman LA. The incidence of duplicate genetic testing. Genet Med 2008;10:114-116.
18. Hull RD, Pineo GF, Brant RF, et al. Self-managed long-term low-molecular-weight heparin therapy: the balance of benefits and harms. Am J Med 2007;120:72-82.
19. Burke W, Psaty BM. Personalized medicine in the era of genomics. JAMA 2007;298:1682-1684.
20. Morgan MA, Driscoll DA, Mennuti MT, Schulkin J. Practice patterns of obstetrician-gynecologists regarding preconception and prenatal screening for cystic fibrosis. Genet Med 2004;6:450-455.
21. Driscoll DA, Morgan MA, Schulkin J. Screening for Down syndrome: changing practice of obstetricians. Am J Obstet Gynecol 2009;200: 459.e1-e9.